Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.

Hiret S, Isambert N, Gomez-Roca C, Bennouna J, Sassi M, de Mont-Serrat H, Fan J, Schnell D, Delord JP.

Invest New Drugs. 2018 May 29. doi: 10.1007/s10637-018-0601-1. [Epub ahead of print]

PMID:
29808308
2.

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.

Marmé F, Gomez-Roca C, Graudenz K, Huang F, Lettieri J, Peña C, Trnkova ZJ, Eucker J.

Cancer Chemother Pharmacol. 2018 Apr;81(4):727-737. doi: 10.1007/s00280-018-3540-9. Epub 2018 Feb 21.

PMID:
29468456
3.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, Ejadi S, Piha-Paul SA, Stein MN, Abdul Razak AR, Dotti K, Santoro A, Cohen RB, Gould M, Saraf S, Stein K, Han SW.

PLoS One. 2017 Dec 28;12(12):e0189848. doi: 10.1371/journal.pone.0189848. eCollection 2017.

4.

Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.

Massabeau C, Khalifa J, Filleron T, Modesto A, Bigay-Gamé L, Plat G, Dierickx L, Aziza R, Rouquette I, Gomez-Roca C, Mounier M, Delord JP, Toulas C, Olivier P, Chatelut E, Mazières J, Cohen-Jonathan Moyal E.

Clin Lung Cancer. 2018 May;19(3):e277-e285. doi: 10.1016/j.cllc.2017.11.002. Epub 2017 Nov 21.

PMID:
29221762
5.

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A.

J Clin Oncol. 2017 Dec 20;35(36):4035-4041. doi: 10.1200/JCO.2017.74.5471. Epub 2017 Nov 2.

PMID:
29095678
6.

Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.

Ravaud A, Gomez-Roca C, Picat MQ, Digue L, Chevreau C, Gimbert A, Chauzit E, Sitta R, Cornelis F, Asselineau J, Aziza R, Daste A, Quemener C, Baud J, Bikfalvi A, Pedenon-Périchout D, Doussau A, Molimard M, Delord JP.

Eur J Cancer. 2017 Nov;85:39-48. doi: 10.1016/j.ejca.2017.07.031. Epub 2017 Sep 5.

PMID:
28886476
7.

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.

Aboudaram A, Modesto A, Chaltiel L, Gomez-Roca C, Boulinguez S, Sibaud V, Delord JP, Chira C, Delannes M, Moyal E, Meyer N.

Melanoma Res. 2017 Oct;27(5):485-491. doi: 10.1097/CMR.0000000000000386.

PMID:
28858075
8.

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.

Hollebecque A, Bahleda R, Faivre L, Adam J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, Gazzah A, Ileana E, Gharib M, Angevin E, Malekzadeh K, Massard C, Soria JC, Spano JP.

Eur J Cancer. 2017 Aug;81:81-89. doi: 10.1016/j.ejca.2017.05.021. Epub 2017 Jun 12.

PMID:
28618305
9.

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.

Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan R, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart DD, Moutouh-de Parseval L, Demuth T, Dummer R.

Clin Cancer Res. 2017 Sep 15;23(18):5339-5348. doi: 10.1158/1078-0432.CCR-16-2923. Epub 2017 Jun 13.

10.

Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors.

Bétrian S, Gomez-Roca C, Vigarios E, Delord JP, Sibaud V.

JAMA Dermatol. 2017 Jul 1;153(7):723-725. doi: 10.1001/jamadermatol.2017.0500. No abstract available.

PMID:
28538953
11.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.

Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J.

Ann Oncol. 2017 May 1;28(5):1036-1041. doi: 10.1093/annonc/mdx029.

12.

Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings.

Sibaud V, Eid C, Belum VR, Combemale P, Barres B, Lamant L, Mourey L, Gomez-Roca C, Estilo CL, Motzer R, Vigarios E, Lacouture ME.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):e464-e469. doi: 10.1111/jdv.14284. Epub 2017 May 8. No abstract available.

PMID:
28419570
13.

Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma.

Auclin E, Bourillon C, De Maio E, By MA, Seddik S, Fournier L, Auvray M, Dautruche A, Vano YA, Thibault C, Joly F, Brunereau L, Gomez-Roca C, Chevreau C, Elaidi R, Oudard S.

Clin Genitourin Cancer. 2017 Jun;15(3):350-355. doi: 10.1016/j.clgc.2017.01.022. Epub 2017 Feb 1.

PMID:
28216276
14.

Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?

Khalifa J, Tensaouti F, Lotterie JA, Catalaa I, Chaltiel L, Benouaich-Amiel A, Gomez-Roca C, Noël G, Truc G, Péran P, Berry I, Sunyach MP, Charissoux M, Johnson C, Cohen-Jonathan Moyal E, Laprie A.

J Neurooncol. 2016 Oct;130(1):181-192. Epub 2016 Aug 8.

PMID:
27502603
15.

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.

Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HM, van der Graaf WT, Christen R, Rüttinger D, Weigand S, Cannarile MA, Heil F, Brewster M, Walz AC, Nayak TK, Guarin E, Meresse V, Le Tourneau C.

Oncotarget. 2016 Nov 29;7(48):80046-80058. doi: 10.18632/oncotarget.11098.

16.

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.

Vey N, Delaunay J, Martinelli G, Fiedler W, Raffoux E, Prebet T, Gomez-Roca C, Papayannidis C, Kebenko M, Paschka P, Christen R, Guarin E, Bröske AM, Baehner M, Brewster M, Walz AC, Michielin F, Runza V, Meresse V, Recher C.

Oncotarget. 2016 May 31;7(22):32532-42. doi: 10.18632/oncotarget.8687.

17.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H.

Lancet Haematol. 2016 Apr;3(4):e186-95. doi: 10.1016/S2352-3026(15)00247-1. Epub 2016 Mar 18.

PMID:
27063977
18.

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.

Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte Rouge T, Uro-Coste E, de Braud F, Pelosi G, French CA.

Cancer Discov. 2016 May;6(5):492-500. doi: 10.1158/2159-8290.CD-15-1335. Epub 2016 Mar 14.

19.

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.

Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Müller C, Jegg AM, Bröske AM, Dembowski M, Bray-French K, Freilinger C, Meneses-Lorente G, Baehner M, Harding R, Ratnayake J, Abiraj K, Gass N, Noh K, Christen RD, Ukarma L, Bompas E, Delord JP, Blay JY, Rüttinger D.

Lancet Oncol. 2015 Aug;16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12.

PMID:
26179200
20.

Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.

Isambert N, Delord JP, Soria JC, Hollebecque A, Gomez-Roca C, Purcea D, Rouits E, Belli R, Fumoleau P.

Ann Oncol. 2015 May;26(5):1005-11. doi: 10.1093/annonc/mdv031. Epub 2015 Feb 2.

PMID:
25646368
21.

Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.

Vigarios E, Lamant L, Delord JP, Fricain JC, Chevreau C, Barrés B, Gomez-Roca C, Boulanger M, Sibaud V.

Br J Dermatol. 2015 Jun;172(6):1680-2. doi: 10.1111/bjd.13610. Epub 2015 Apr 19. No abstract available.

PMID:
25495246
22.

Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.

Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB.

Clin Cancer Res. 2014 Nov 15;20(22):5663-71. doi: 10.1158/1078-0432.CCR-14-0719. Epub 2014 Sep 24.

23.

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Rüttinger D.

Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2.

24.

Emerging new anticancer therapies in 2013.

Gomez-Roca C, Delord JP.

Curr Opin Oncol. 2014 May;26(3):357-62. doi: 10.1097/CCO.0000000000000081. Review.

PMID:
24709976
25.

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schöffski P, Voest EE, Gomez-Roca C, Evans TR, Plummer R, Gallerani E, Kaye SB, Olmos D.

Ann Oncol. 2014 Jun;25(6):1222-8. doi: 10.1093/annonc/mdu108. Epub 2014 Mar 7.

PMID:
24608201
26.

Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma.

Delord JP, Tabernero J, García-Carbonero R, Cervantes A, Gomez-Roca C, Bergé Y, Capdevila J, Paz-Ares L, Roda D, Delmar P, Oppenheim D, Brossard SS, Farzaneh F, Manenti L, Passioukov A, Ott MG, Soria JC.

Eur J Cancer. 2014 Feb;50(3):496-505. doi: 10.1016/j.ejca.2013.10.015. Epub 2013 Nov 18.

PMID:
24262587
27.

Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.

Ferté C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, Balheda R, Bot B, Gomez-Roca C, Dromain C, Ammari S, Soria JC.

Clin Cancer Res. 2014 Jan 1;20(1):246-52. doi: 10.1158/1078-0432.CCR-13-2098. Epub 2013 Nov 15.

28.

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.

Hollebecque A, Deutsch E, Massard C, Gomez-Roca C, Bahleda R, Ribrag V, Bourgier C, Lazar V, Lacroix L, Gazzah A, Varga A, de Baere T, Beier F, Kroesser S, Trang K, Zenke FT, Klevesath M, Soria JC.

Invest New Drugs. 2013 Dec;31(6):1530-8.

PMID:
24077982
29.

Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trials.

Levy A, Gomez-Roca C, Massard C, Planchard D, Albiges L, Bahleda R, Bourgier C, Deutsch E, Soria JC, Besse B.

Onkologie. 2013;36(6):357-62. doi: 10.1159/000351257. Epub 2013 May 13.

PMID:
23774150
30.

[Role of high-throughput sequencing in oncology].

Rodrigues MJ, Gomez-Roca C.

Bull Cancer. 2013 Mar;100(3):295-301. doi: 10.1684/bdc.2013.1717. Review. French.

PMID:
23501647
31.

Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer.

Massard C, Borget I, Le Deley MC, Taylor M, Gomez-Roca C, Soria JC, Farace F.

Eur J Cancer. 2012 Jun;48(9):1354-62. doi: 10.1016/j.ejca.2012.01.021. Epub 2012 Feb 25.

PMID:
22370181
32.

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB.

J Clin Oncol. 2012 Mar 20;30(9):996-1004. doi: 10.1200/JCO.2010.34.5074. Epub 2012 Feb 21.

PMID:
22355064
33.

Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants - reply to Fussenich et al.: a new, simple and objective prognostic score for phase I cancer patients.

Olmos D, Ang JE, Gomez-Roca C, Morales-Barrera R, Vulink AJ, Massard C, Kaye S; EDDN.

Eur J Cancer. 2012 Mar;48(4):594-6. doi: 10.1016/j.ejca.2011.11.004. Epub 2011 Dec 7. No abstract available.

PMID:
22154652
34.

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.

Gomez-Roca CA, Lacroix L, Massard C, De Baere T, Deschamps F, Pramod R, Bahleda R, Deutsch E, Bourgier C, Angevin E, Lazar V, Ribrag V, Koscielny S, Chami L, Lassau N, Dromain C, Robert C, Routier E, Armand JP, Soria JC.

Ann Oncol. 2012 May;23(5):1301-6. doi: 10.1093/annonc/mdr383. Epub 2011 Sep 14.

PMID:
21917737
35.

Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.

Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Bergé Y, Roda D, Russell-Yarde F, Hollingsworth S, Baselga J, Umana P, Manenti L, Tabernero J.

J Clin Oncol. 2011 Oct 1;29(28):3783-90. doi: 10.1200/JCO.2011.34.8888. Epub 2011 Sep 6.

PMID:
21900113
36.

Tumour growth rates and RECIST criteria in early drug development.

Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, Bahleda R, Ferté C, Massard C, Soria JC.

Eur J Cancer. 2011 Nov;47(17):2512-6. doi: 10.1016/j.ejca.2011.06.012. Epub 2011 Jul 15.

PMID:
21763126
37.

Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.

Levy A, Albiges-Sauvin L, Massard C, Izzedine H, Ederhy S, Bahleda R, Gomez-Roca C, Chargari C, Brocheriou-Spelle I, Soria JC.

Invest New Drugs. 2012 Jun;30(3):1116-20. doi: 10.1007/s10637-011-9671-z. Epub 2011 Apr 21. Erratum in: Invest New Drugs. 2012 Jun;30(3):1276. Edhery, Stéphane [corrected to Ederhy, Stéphane].

PMID:
21509469
38.

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

Ferté C, Paci A, Zizi M, Gonzales DB, Goubar A, Gomez-Roca C, Massard C, Sahmoud T, André F, Soria JC.

Eur J Cancer. 2011 Oct;47(15):2249-55. doi: 10.1016/j.ejca.2011.03.017. Epub 2011 Apr 12.

PMID:
21489779
39.

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

Postel-Vinay S, Gomez-Roca C, Molife LR, Anghan B, Levy A, Judson I, De Bono J, Soria JC, Kaye S, Paoletti X.

J Clin Oncol. 2011 May 1;29(13):1728-35. doi: 10.1200/JCO.2010.31.9236. Epub 2011 Mar 28.

PMID:
21444876
40.

Rhinitis in patients treated with a combination of an mTOR inhibitor and an EGFR inhibitor.

Prulière-Escabasse V, Gomez-Roca C, Escudier E, Coste A, Besse B, Massard C, Soria JC.

Onkologie. 2010;33(7):401-2. doi: 10.1159/000315757. Epub 2010 Jun 22. No abstract available.

PMID:
20631489
41.

Pemetrexed-induced pneumonitis: a case report.

Loriot Y, Ferte C, Gomez-Roca C, Moldovan C, Bahleda R, Wislez M, Cadranel J, Soria JC.

Clin Lung Cancer. 2009 Sep;10(5):364-6. doi: 10.3816/CLC.2009.n.050.

PMID:
19808196
42.

Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors.

Hartl DM, Ferté C, Loriot Y, Gomez Roca C, Bahleda R, Moldovan C, Mir O, Soria JC.

Invest New Drugs. 2010 Dec;28(6):884-6. doi: 10.1007/s10637-009-9314-9. Epub 2009 Sep 16. No abstract available.

PMID:
19756374
43.

Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.

Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC.

J Thorac Oncol. 2009 Oct;4(10):1212-20. doi: 10.1097/JTO.0b013e3181b44321.

44.

Reversible cardiogenic shock following 5-fluorouracil infusion.

Ferté C, Gomez Roca C, Loriot Y, Bahleda R, Moldovan C, Cohen A, Izzedine H, Soria JC, Ederhy S.

Invest New Drugs. 2010 Aug;28(4):531-3. doi: 10.1007/s10637-009-9271-3. Epub 2009 Jun 5.

PMID:
19499187
45.

Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases.

Raynaud CM, Mercier O, Commo F, Dartevelle P, Gomez-Roca C, de Montpreville V, Sabatier L, Soria JC.

Lung Cancer. 2009 Aug;65(2):144-9. doi: 10.1016/j.lungcan.2008.10.030. Epub 2008 Dec 16.

PMID:
19091442
46.

[Prognostic risk factors for serious complications in an inpatient population with neutropenia at the onset of a febrile episode].

Gómez Roca C, Rivero M, Hugo K, Novillo A, Marta Lapadula M, Recondo G, Milberg M.

Medicina (B Aires). 2006;66(5):385-91. Spanish.

PMID:
17137166

Supplemental Content

Loading ...
Support Center